Hyperscale Data Sets Investor Day but Omits Critical Phase 1 Update

What happened

Hyperscale Data announced a virtual investor day on November 12, 2026, to discuss Michigan AI expansion and strategic alternatives, while reiterating 2027 guidance of $300–$350 million revenue and $60–$80 million adjusted EBITDA. The press release is silent on the company's previously targeted Phase 1 10MW 'ready-for-service' milestone, which was contractually due September 21, 2026, according to a June 2026 8-K. The omission is notable because the DeepValue master report identified that deadline as the single most important near-term proof point for the AI colocation thesis. The announcement also formalizes 'strategic alternatives' discussions, which were previously disclosed as a long-term value-unlock mechanism, but could signal financial pressure given the company's heavy dilution and cash burn. Without confirmation of Phase 1 delivery, the reiterated 2027 guidance lacks credibility and appears more promotional than substantive.

Implication

The investor day may provide details on AI expansion and strategic alternatives, but investors should focus on concrete proof of the Sep 21 Phase 1 delivery. If Phase 1 was missed, the thesis breaks and downside risk increases significantly. Even if delivered, the company still faces a $100–$120 million retrofit funding gap that is being filled through dilutive equity issuance. The reiterated 2027 guidance of $300–$350 million revenue appears aggressive relative to current annualized revenue of ~$176 million and does not address the path to profitability. Strategic alternatives could include divestitures of non-core assets, but such moves would take time and may not solve the near-term liquidity crunch. Overall, the risk/reward remains unattractive until there is clear evidence of operational execution and a shift away from heavy dilution.

Thesis delta

No fundamental change to the investment thesis; the announcement is a communication event. The reiterated 2027 guidance is not supported by disclosed progress on the Phase 1 milestone, which was due Sep 21, 2026. The WAIT rating remains appropriate until the company provides concrete evidence of Phase 1 delivery and a reduction in dilution.